HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Clinical trial NCT03940352 · TERMINATED
Trial details
- NCT number
- NCT03940352
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-24
- Primary completion
- 2024-08-20
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.